Tumor- and stromal cell-specific expression of topoisomerase IIα and HER-2/neu in primary and recurrent ovarian cancer: Results of a prospective study

Molecular Medicine Reports

Volumn 2, Issue 6, 2009, Pages 1011-1016

  Chekerov, Radoslav ^a   Koensgen, Dominique ^b   Klaman, Irina ^c   Rosenthal, André ^c   Oskay Oezcelik, Guelten ^a   Mustea, Alexander ^b   Lichtenegger, Werner ^a   Dahl, Edgar ^d   Sehouli, Jalid ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF GREIFSWALD   (Germany)

^c Signature Diagnostics   (Germany)

^d UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

HER 2 neu; Immunohistochemistry; Ovarian cancer; Topoisomerase II

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); EPIDERMAL GROWTH FACTOR RECEPTOR 2; PLATINUM; TOPOISOMERASE IIALPHA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; CORRELATION ANALYSIS; EPITHELIUM TUMOR; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; OVARY CANCER; PRIMARY TUMOR; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RECURRENT CANCER; STROMA CELL; TISSUE SECTION;

EID: 73649114253     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr_00000207     Document Type: Article

References (38)

1. Pfisterer J and du Bois A: Das Ovarialkarzinom: therapeutische standards - Klinische Empfehlungen. Stuttgart, Georg Thieme Verlag, 2001.
2. Ferlay J, Autier P, Boniol M, et al: Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 18: 581-592, 2007.
3. Sehouli J, Koensgen D, Mustea A, et al: 'IMO' - intraoperative mapping of ovarian cancer. Zentralbl Gynakol 125: 129-135, 2003.
4. Heintz AP, Odicino F, Maisonneuve P, et al: Carcinoma of the ovary. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 95 (Suppl 1): 161-192, 2006.
5. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL and Montz FJ: Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20: 1248-1259, 2002.
6. Schindlbeck C, Hantschmann P, Zerzer M, et al: Prognostic impact of KI67, p53, human epithelial growth factor receptor 2, topoisomerase IIalpha, epidermal growth factor receptor, and nm23 expression of ovarian carcinomas and disseminated tumor cells in the bone marrow. Int J Gynecol Cancer 17: 1047-1055, 2007.
7. Helleman J, Jansen MP, Span PN, et al: Molecular profiling of platinum resistant ovarian cancer. Int J Cancer 118: 1963-1971, 2006.
8. Gotlieb WH, Goldberg I, Weisz B, Davidson B, Novikov I, Kopolovic J and Ben-Baruch G: Topoisomerase II immuno-staining as a prognostic marker for survival in ovarian cancer. Gynecol Oncol 82: 99-104, 2001.
9. Heck MM and Earnshaw WC: Topoisomerase II: A specific marker for cell proliferation. J Cell Biol 103: 2569-2581, 1986.
10. Wang J: Cellular roles of DNA topoisomerases: a molecular perspective. Nat Rev Mol Cell Biol 3: 430-440, 2002.
11. Burden DA and Osheroff N: Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzyme. Biochim Biophys Acta 1400: 139-154, 1998.
12. Larsen AK and Skladanowski A: Cellular resistance to topoisomerase- targeted drugs: from drug uptake to cell death. Biochim Biophys Acta 1400: 257-274, 1998.
13. Hengstler JG, Lange J, Kett A, et al: Contribution of c-erbB-2 and topoisomerase IIalpha to chemoresistance in ovarian cancer. Cancer Res 59: 3206-3214, 1999.
14. Jarvinen TA and Liu ET: Simultaneous amplification of HER-2 (ERBB2) and topoisomerase IIalpha (TOP2A) genes - molecular basis for combination chemotherapy in cancer. Curr Cancer Drug Targets 6: 579-602, 2006.
15. Slamon DJ, Godolphin W, Jones LA, et al: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707-712, 1989.
16. Meden H and Kuhn W: Overexpression of the oncogene c-erbB-2 (HER2/neu) in ovarian cancer: a new prognostic factor. Eur J Obstet Gynecol Reprod Biol 71: 173-179, 1997.
17. Serrano-Olvera A, Duenas-Gonzalez A, Gallardo-Rincon D, Candelaria M and De la Garza-Salazar J: Prognostic, predictive and therapeutic implications of HER2 in invasive epithelial ovarian cancer. Cancer Treat Rev 32: 180-190, 2006.
18. Tuefferd M, Couturier J, Penault-Llorca F, et al: HER2 status in ovarian carcinomas: A multicenter GINECO study of 320 patients. PLoS ONE 2: e1138, 2007.
19. Simon R, Atefy R, Wagner U, et al: HER-2 and TOP2A gene amplification in urinary bladder cancer. Verh Dtsch Ges Pathol 86: 176-183, 2002.
20. Cornarotti M, Capranico G, Bohm S, et al: Gene expression of DNA topoisomerases I, II alpha and II beta and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Int J Cancer 67: 479-484, 1996.
21. Mano MS, Awada A, Di Leo A, et al: Rates of topoisomerase II-alpha and HER-2 gene amplification and expression in epithelial ovarian carcinoma. Gynecol Oncol 92: 887-895, 2004.
22. Tlsty TD and Hein PW. Know thy neighbor: stromal cells can contribute oncogenic signals. Curr Opin Genet Dev 11: 54-59, 2001.
23. Tanner B, Pilch H, Schäffer U, et al: Expression of c-erbB-2 and topoisomerase II alpha in relation to chemoresistance in ovarian cancer. Zentralbl Gynakol 124: 176-183, 2002.
24. Pritchard KI: HER-2 and topoisomerase II as predictors of response to chemotherapy. J Clin Oncol 26: 736-744, 2008.
25. Simon R, Atefy R, Wagner U, et al: HER-2 and TOP2A coamplification in urinary bladder cancer. Int J Cancer 107: 764-772, 2003.
26. Park CC, Bissell MJ and Barcellos-Hoff MH: The influence of the microenvironment on the malignant phenotype. Mol Med Today 6: 324-329, 2000.
27. Krtolica A and Campisi J: Cancer and aging: a model for the cancer promoting effects of the aging stroma. Int J Biochem Cell Biol 34: 1401-1414, 2002.
28. DePinho RA: The age of cancer. Nature 408: 248-254, 2000.
29. Tlsty TD: Stromal cells can contribute oncogenic signals. Semin Cancer Biol 11: 97-104, 2001.
30. Chrenek MA, Wong P and Weaver VM: Tumor-stromal interactions. Integrins and cell adhesions as modulators of mammary cell survival and transformation. Breast Cancer Res 3: 224-229, 2001.
31. Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD and Cunha GR: Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res 59: 5002-5011, 1999.
32. Tuxhorn JA, Ayala GE, Smith MJ, Smith VC, Dang TD and Rowley DR: Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling. Clin Cancer Res 8: 2912-2923, 2002.
33. Skobe M and Fusenig NE: Tumorigenic conversion of immortal human keratinocytes through stromal cell activation. Proc Natl Acad Sci USA 95: 1050-1055, 1998.
34. Sternlicht MD, Lochter MD, Sympson CJ, et al: The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis. Cell 98: 137-146, 1999.
35. Barcellos-Hoff MH and Ravani SA: Irradiated mammary gland stroma promotes the expression of tumorigenic potential by unirradiated epithelial cells. Cancer Res 60: 1254-1260, 2000.
36. Bingham C, Roberts D and Hamilton TC: The role of molecular biology in understanding ovarian cancer initiation and progression. Int J Gynecol Cancer 11: 7-11, 2001.
37. See HT and Kavanagh JJ: Novel agents in epithelial ovarian cancer. Cancer Invest 22: 29-44, 2004.
38. Kaufmann SH: Cell death induced by topoisomerase-targeted drugs: more questions than answers. Biochim Biophys Acta 1400: 195-211, 1998.